CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: Biological concepts with a review of the literature

Implant Dentistry

Volumn 18, Issue 6, 2009, Pages 492-500

  Lee, Cameron Y S ^a   Suzuki, Jon B ^b  

^a Maxillofacial and Reconstructive Surgery   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ARTICLE; BLOOD; BONE NECROSIS; BONE REMODELING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FORECASTING; HUMAN; JAW DISEASE; METABOLISM; ORAL SURGERY; OSTEOCLAST; OSTEOLYSIS; PHYSIOLOGY;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; COLLAGEN TYPE I; DIPHOSPHONATES; FORECASTING; HUMANS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEOCLASTS; OSTEONECROSIS; PEPTIDES;

EID: 74049083629     PISSN: 10566163     EISSN: None     Source Type: Journal    
DOI: 10.1097/ID.0b013e3181c6837c     Document Type: Article

References (82)

1. Orwoll ES, Bell NH, Nanes MS, et al. Collagen N-telopeptide excretion in men: The effects of age and intrasubject variability. J Clin Endoclinol Metab. 1998;83: 3930-3935.
2. Greenspan SL, Rosen HN, Parker RA. Early changes in serum n-telopeptide and c-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537-3540.
3. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk-factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg. 2007;65:2397-2410.
4. Neff MJ. Practical guidelines: ACOG releases guidelines for clinical management of osteoporosis. Am Fam Physician. 2004;69:1-9.
5. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg. 2009; 67:850-855.
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.
8. Lee CYSL, David T, Nishime M. Use of platelet rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: A report of 2 cases. J Oral Implantol. 2007;33:371-382.
9. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21:349-353.
10. Nase JB, Suzuki JB. Osteonecrosis of the jaws and oral bisphosphonate treatment. J Am Dent Assoc. 2006;137: 1115-1119.
11. Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. An institutional inquiry. J Am Dent Assoc. 2009;140:61-66.
12. Wang HL, Weber D, McCauley LK, et al. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report. J Periodontol. 2007;78:584-594.
13. Edwards BJ, Migliorati CA. Osteoporosis and its implications for dental patients. J Am Dent Assoc. 2008;139: 545-552.
14. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88:2095-2105.
15. Licata AA. Discovery, clinical development and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005;39: 668-677.
16. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:259-260.
17. Rauch F, Glorieux FH. Osteogenesis imperfect. Lancet. 2004;363:1377-1385.
18. Kanis JA, Gertz BJ, Singer F, et al. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int. 1995;5: 1-13.
19. Stewart A. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;353:373-375.
20. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349:457-463.
21. Berenson J. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10: 52-63.
22. Melo M, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71:111-113.
23. Engroff S, Kim D. Treating bisphosphonate osteonecrosis of the jaws: Is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg. 2007;65: 2374-2385
24. Fleisher KE, Doty S, Kottal S, et al. Tetracycline-guided debridement and cone bam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: A technical note. J Oral Maxillofac Surg. 2008;66:2646-2653.
25. Lam DK, Sandor GKB, Holmes HI, et al. A review of bisphosphonateassociated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007; 73:417-422.
26. Assael LA. Editorial: Serum CTX to prevent osteonecrosis/orthodontic extraction of third molars: Paths toward minimizing surgical risk? J Oral Maxillofac Surg. 2007;65:2395-2396.
27. Schwartz HC. Serum CTX testing. J Oral Maxillofac Surg. 2008;66:1319-1320.
28. Khosla S, Burr D, Cawley J, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008;66:1320-1321.
29. Zak M, Spina AM, Spinazze RP, et al. Bisphosphonates and the dental patient: Part 2. Compend. 2007;28:510-516.
30. Koka S. Osteonecrosis of the jaw and biomarkers: What do we tell our patients? Int J Oral Maxillofac Implants. 2008; 23:179-180 (Editorial).
31. Bilezikian JP, Raisz LG, Martin TJ. Principles of Bone Biology. Biochemical Markers of Bone Metabolism. San Diego: Elsevier Inc.; 2008:285-1881.
32. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol. 2005;90:1294-1301.
33. Ciarella TE, Fyhrie DP, Parfitt AM. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone. 2003;32:311-315.
34. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol. 2000;85:3109-3115.
35. Kleerekoper M. Biochemical markers of bone turnover: Why theory, research, and clinical practice are still in conflict. Clin Chem. 2001;47:1347-1349.
36. Chailurkit LO, Ongphiphadhanakul B, Piaseu N, et al. Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: An experience in a clinical laboratory. Clin Chem. 2001;47: 1083-1088.
37. Garnero P, Borel O, Delmas P. Evaluation of a fully automated serum assay for c-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clini Chem. 2001;47:694-702.
38. Lin JH. Bisphosphonates: a review of their pharmokinetic properties. Bone. 1996;18:75-85.
39. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9:2643-2658.
40. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.
41. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538-6543.
42. Wood J, Bongean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharm Exp Thesopuctus. 2002; 302:1055-1063.
43. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol. 1997;98:665-672.
44. Rogers MJ. From moulds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 2004;75:451-461.
45. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5:65-74.
46. Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001; 29:553-559.
47. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60:6001-6007.
48. Pan B, To LB, Farrugia AN, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralization of human bone-derived cells in vitro. Bone. 2004;34:112-123.
49. Im G-I, Qureshi SA, Kenney J, et al. Osteoblast proliferation and maturation by bisphosphonates. Biomat. 2004;25:4105-4115.
50. Kearns AE, Khosla S, Kosteniuk P. RANKL and OPG regulation of bone remodeling in health and disease. Endocrinol Rev. 2007;22:477-501.
51. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
52. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999;96:3540-3545.
53. Khosla S. Minireview: the OPG/ RANKL/RANK system. Endocrinol. 2001; 142:5050-5055.
54. Quinn JM, Itoh K, Udagawa N, et al. Transforming growth factor B effects on osteoclasts differentiation via direct and indirect actions. J Bone Miner Res. 2001;16: 787-794.
55. Naidu A, Dechow PC, Spears R, et al. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:5-13.
56. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304-1306.
57. Carter GD, Gross AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. 2003;48:268-273.
58. Dimitrikopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: A clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006;35:588-593.
59. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphohphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136: 1658-1668.
60. Markiewicz MR, Margarone JE, Campbell JH, et al. Bisphosphonateassociated osteonecrosis of the jaws: A review of current knowledge. J Am Dent Assoc. 2005;136:1669-1674.
61. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc. 2005;136:1675-1681.
62. Kraut RA. Bisphosphonate therapy. Implant Dent. 2006;15:322.
63. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7:508-514.
64. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005; 23:8580-8587.
65. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328-1331.
66. Lexi-comp. Alendronate: Drug information. Whitehouse Station N, NJ: Merck & Co; 2008.
67. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg. 2007;65: 369-376.
68. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423.
69. Van den Wyngaert T, Huizing M, Vermorken J. Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy? Ann Oncol. 2006;17: 1197-1204.
70. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg. 2008;66:625-631.
71. Glick M. Closing in on the puzzle of ONJ. J Am Dent Assoc. 2008;139:12-15.
72. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the serum crosslaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 1998;44:2290-2300.
73. Rosenquist C, Fledelius C, Christgau S, et al. Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clinical Chemistry. 1998;44:2281-2289.
74. Dresner-Pollak R, Parker RA, Poku M, et al. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int. 1996;59:328-333.
75. Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337-349.
76. Christgau S, Bitsch-Jensen O, Bjarnason NH, et al. Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 2000;26:505-511.
77. Harris ST, Gertz BJ, Genant HK, et al. The effects of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76:1399-1406.
78. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 1999;24:237-244.
79. Nguyen TV, Sambrook PN, Eisman JA. Source of variability in bone mineral density measurement: implications for study design and analysis of bone loss. J Bone Miner Res. 1997;45:1359-1368.
80. Eyre DR. Collagen cross-linking amino acids. Methods Enzymol. 1987; 144:115-139.
81. Rosen HN, Moses AC, Garber J, et al. Serum CTx: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100-103.
82. Delmas PD. Biochemical markers of bone turnover. J Bone Miner Res. 1993;8:549-555.